David Blough, PhD, Research Associate Professor of Pharmacy
dkblough@u.washington.edu

Dr. Blough earned his PhD in Statistics at Iowa State University. He has served as collaborating statistician on numerous research projects within the department including research on asthma, risk of seizures associated with tramadol, adverse drug reactions in the elderly and the evaluation of reference-based pricing in British Columbia.

In addition, Dr. Blough has contributed to medical risk adjustment methodology and to the development of risk adjustment technology . His areas of emphasis are generalized linear models, the analysis of longitudinal data and mixed models.

Denise Boudreau, MS, PhD, Affiliate Associate Professor of Pharmacy
Department of Pharmacy
dboudrea@u.washington.edu

Denise Boudreau, PhD earned her doctorate in Pharmaceutical Outcomes Research and Policy from the University of Washington in 2002, and both master's degree in Pharmacy Administration in 1996 and B.Pharm in 1992 from the University of Rhode Island.  She is a Research Scientist at the United BioSource Corporation and an affiliate Associate Professor in the Department of Pharmacy at the University of Washington.  From 2003-2007, Dr. Boudreau worked as a Scientific Investigator at Group Health Center for Health Studies where she remains an affiliate faculty member.  She was the Group Health site Principal Investigator for the HMO Research Network Center for Education and Research on Therapeutics (CERT) from 2004-2007.

Dr. Boudreau is involved in a wide array of pharmacoepidemiology and pharmacoeconomic research. She has conducted research in multiple areas, including: general drug safety, medication use and cancer risk, validation of pharmaceutical data sources, cost and effect of medication use on breast cancer biologic and screening endpoints, cost utility of measures to improve mammography screening, economic burden of metabolic syndrome, and pharmacy practice patterns. Her current research projects include: determinants and risks of long term opioid therapy, impact of commonly used medications on breast cancer outcomes, and cost of false positive mammography.

Brian Bresnahan, PhD, Assistant Professor (Adjunct) Department of Radiology
bres@u.washington.edu

In November 2007, Brian W. Bresnahan joined the Faculty of the University of Washington, Department of Radiology, in Seattle, WA, as a Research Assistant Professor in the Health Services Research section.  Dr. Bresnahan, a health economist, also supports the Harborview Medical Center, Department of Radiology through collaboration on economic evaluations, research projects, and quality improvement initiatives. 
Most recently, from 2005-2007, Brian was working as a Senior Post-Doctoral Fellow sponsored by Eli Lilly & Company, in the Pharmaceutical Outcomes Research & Policy Program of the Department of Pharmacy at the University of Washington. 

Previously, for seven years, he worked as a health economist in the pharmaceutical and bio-technology industry for Johnson & Johnson and Genentech.  He has worked in multiple disease areas, including: asthma, bipolar disorder and mental health, cancer-related anemia, dermatologic conditions, and diseases of the central nervous system.   Prior to this, he worked for Westat, Inc., a survey research firm, as a programmer and analyst on the Medical Expenditures Panel Survey (MEPS).  Before this, he was a Visiting Professor at Louisiana State University and an Instructor at the University of Georgia, where he received his Ph.D. in Economics.  He received his B.S. from Mount Saint Mary’s College, in Emmitsburg, Maryland.

Dr. Bresnahan’s research interests include health outcomes research, health technology assessment, risk-benefit assessment, cost-effectiveness analysis, and health preference evaluation.  His current research involves an economic evaluation of a carpal tunnel syndrome study and assessing how payers define and evaluate medical product value in their decision-making processes.  He is also working with researchers in the UW Department of Pharmacy on a measles vaccination innovation project funded by the Bill and Melinda Gates Foundation, and is conducting a program evaluation with Premera Blue Cross assessing pharmacy and medical claims for a higher-risk polypharmacy sub-population.

Rick Carlson, JD, Clinical Professor, Health Services, Affiliate Professor, Department of Pharmacy
RickJCarl@aol.com

Mr. Carlson has over a thirty-five year career in health care strategy and policy that began with active involvement in the evolution of HMO's and managed care. He also serves a number of health and health care organizations as a special advisor both as to the strategic evolution of managed care and as to evolving and emerging programs, projects and managed care, and "products and services" related to the individual and the family's needs for self care and self management of healthcare information and services.

More recently, he has begun to focus on the mapping of the human genome and the tidal wave of implications for human health, the delivery of health care services, and today's health care delivery system.

He is also President of the Health Strategies Group, Seattle, WA and Aspen, CO.

Beth Devine, PharmD, MBA, BCPS, FASHP
Research Associate Professor of Pharmacy
bdevine@u.washington.edu

Dr. Devine has been a member of the faculty in the UW Pharmaceutical Outcomes Program since 2001. Prior to that time she completed a fellowship in the UW Pharmaceutical Outcomes Program, spending one year with Roche Pharma Business, Health Economics and Strategic Pricing Group, in Palo Alto, CA. Her current research interests are in the area of patient safety; specifically the impact of technology on decreasing medication errors and adverse drug events. Related interests include assessing prescriber attitudes to electronic prescribing and the cost-benefit of electronic prescribing. Her other interests are in quality of life and the cost-effectiveness of hepatitis C therapies. Dr. Devine has as background in clinical pharmacy practice and administration, both in the academic setting. Dr. Devine earned her doctorate in Pharmacy from the University of the Pacific and her MBA from the University of San Francisco. She completed her residency in clinical pharmacy practice at the Veterans Affairs Medical Center in Palo Alto, CA. Dr. Devine is a member of the American Association of Colleges of Pharmacy, the American College of Clinical Pharmacy, the American Medical Informatics Association, and the International Society for Pharmacoeconomics and Outcomes Research. She is a past president of the California Society of Health-System Pharmacists, and has also been active with the American Society of Health-System Pharmacists, currently serving on the editorial board. She is the recipient of a Mentored Clinical Scientist Training Grant (K-08) from the Agency for Healthcare Research and Quality, for her work in health information technology.

Jacqueline Gardner, PhD, Professor of Pharmacy
jsgardne@u.washington.edu

Dr. Gardner earned her degree in Epidemiology from the University of Washington School of Public Health and Community Medicine in 1980. From 1980 to 1992 she worked for The Upjohn Company, ultimately becoming Director of Drug Epidemiology. Gardner’s research focuses on use and effects of drugs in women and children and upon innovative pharmacy practice. Her projects have included examination of the use of hormone replacement therapy by menopausal women and the association of maternal drug use during pregnancy with craniosynostosis. She is responsible for evaluation of demonstration projects designed to explore the outcomes of extending prescriptive authority to pharmacists to provide emergency contraceptive pills, and of management of hyperlipidemia by community pharmacists. Gardner is a member of the Washington State Pharmacists Association, the Drug Information Association and the International Society of Pharmacoepidemiology, American Pharmaceutical Association and the Association of Reproductive Health Professionals.

Louis P. Garrison, Jr., PhD, Professor of Pharmacy
Associate Director, Pharmaceutical Outcomes Research and Policy Program
lgarrisn@u.washington.edu

Dr. Garrison joins us from Roche Pharmaceuticals where he most recently held the position of Vice President and Head of their global Health Economics and Strategic Pricing department. Dr. Garrison received his PhD in economics from Stanford University. He began his career as a research scientist for Battelle Human Affairs Research Centers in Seattle where he focused on physician manpower issues and health technology assessment of dialysis and of kidney and heart transplantation. Garrison next joined the Project HOPE Center for Health Affairs in the Washington D.C. area. He worked there for eight years, eventually becoming the director of the group. At HOPE, he worked on a variety of domestic and international policy issues. On the domestic side, he directed numerous large-scale research and policy projects for a wide variety of agencies, including HHS, CMS, NCHS and NIH. Internationally, he worked on health sector reforms and health training projects in Poland, Jamaica, Grenada, and Panama. He was also the director and principal investigator on projects supporting the Prospective Payment Commission, the 1991 Advisory Council on Social Security, and HHS Secretary Bowen’s Catastrophic Illness Study. At Roche Dr.Garrison performed cost-effectiveness assessments of specific products for indications such as transplantation, influenza, and obesity, and supervised staff responsible for the development of pharmacoeconomic and pricing strategies for all of the products in Roche’s development pipeline. He has also served on the Health Outcomes Committee of the Pharmaceutical Research and Manufacturers Association, the Health Economics Advisory Group to the International Federation of Pharmaceutical Manufacturers Associations, the Ad Hoc Working Group on Economics, and the Patient Reported Outcomes Harmonization Group.

Thomas Hazlet, PharmD., Dr. P.H., Associate Professor of Pharmacy
thazlet@u.washington.edu

Dr. Hazlet completed a doctorate in Pharmacy at the University of California, San Francisco and a residency in hospital pharmacy at Yale-New Haven Hospital. He earned a doctorate in public health in the Health Policy and Administration Program from the School of Public Health at the University of California, Berkeley. His prior experience includes industrial microbiology with Baxter Healthcare Corporation, parenteral nutrition with University of California Los Angeles Medical Center’s Home Parenteral Nutrition Program, and pharmacy practice in a community hospital, a Food and Drug Scientist with the California Department of Health Services’ Food and Drug Branch and a member of the Food and Drug Administration’s Pacific Region Biotechnology Team. His regulatory activities included reviewing investigational new drug applications and acting as technical liaison with field investigator staff, clinical sponsors, industry representatives, and legislators. Dr. Hazlet’s research activities are directed toward assessment of the consequences of pharmaceuticals policy change and have included an evaluation of reference pricing in British Columbia’s Pharmacare pharmaceutical benefit, and 3-tier copayment programs with Washington health insurers. He is also interested in systems analysis of medication errors in community pharmacy practice and automation opportunities for their amelioration.

Srikanth Kadiyala, PhD, Assistant Professor of Pharmacy
harukim@u.washington.edu

Scott Ramsey, M.D., PhD, Professor of Medicine & Pharmacy (Adjunct)
Director, Cancer Outcomes Research Program, Fred Hutchinson Cancer Research Center
sramsey@u.washington.edu

Dr. Ramsey obtained his medical degree from the University of Iowa and a PhD in economics from the Wharton School at the University of Pennsylvania. He completed his residency in internal medicine at the University of Washington, and was Chief Medical Resident for the University Hospital. He also completed a General Internal Medicine fellowship at the Seattle VA Medical Center. He is currently Director of the Cancer Outcomes Research Program at the Fred Hutchinson Cancer Research Center in Seattle. He has served as the Health Analyst for the United States Senate Budget Committee. His areas of interest include methods for economic analyses alongside clinical trials, cost-effectiveness of genetic screening for hereditary colon cancer, quality of life for cancer survivors, and quality of life for colon cancer survivors. His findings from these studies have been published in several journals and presented at numerous national meetings. His current projects include cost-effectiveness and quality of life analyses of colon cancer screening and lung reduction surgery for severe emphysema, an economic evaluation of genetic screening for colorectal cancer susceptibility, and project to compare cost of therapies for advanced lung cancer.

Andy Stergachis, PhD, RPh, Professor of Epidemiology, Adjunct Professor of Pharmacy
stergach@u.washington.edu

Andy Stergachis is Professor of Epidemiology and Adjunct Professor of Pharmacy with the Northwest Center for Public Health Practice, School of Public Health and Community Medicine, University of Washington. His professional areas of interest include pharmacoepidemiology, global health, and public health pharmacy. His current research includes the development of pharmacovigilance models relevant for resource-constrained countries. Andy was formerly Chair of the Department of Pharmacy, Director of PORPP, and Interim Chair of the Department of Pathobiology, University of Washington. From 1998 to 2003, Dr. Stergachis was vice president, chief pharmacist, at drugstore.com, where he defined and implemented innovative Web-based features to promote drug safety and improved consumer decision-making. He was the 1990 Burroughs Wellcome Scholar in Pharmacoepidemiology, has served on NIH's Epidemiology and Disease Control Study Section, AHRQ’s Health Systems Research Study Section, and various committees of the National Committee on Quality Assurance and the Institute of Medicine, including the IOM Committee on the Assessment of the U.S. Drug Safety System. He serves on the Board of the American Pharmacists Association Foundation. Andy supports public health preparedness efforts with local, state, federal, and international health agencies, particularly as they relate to the emergency distribution of pharmaceuticals. He is a Fellow of the International Society for Pharmacoepidemiology, and was awarded the APhA Foundation 2002 Pinnacle Award. He earned his Ph.D. and M.S. from the University of Minnesota and his B.Pharm from Washington State University.

Sean Sullivan, PhD, Professor of Pharmacy, Medicine, and Public Health and Community Medicine; Director, Pharmaceutical Outcomes Research & Policy Program, University of Washington
sdsull@u.washington.edu

Sean D. Sullivan, PhD, is a professor in the Schools of Pharmacy and Public Health/Community Medicine, the Director of the Pharmaceutical Outcomes Research and Policy Program, and an adjunct professor in the Allergy Section of the Department of Medicine at the University of Washington in Seattle. He is an Adjunct Member of the Public Health Sciences Division at the Fred Hutchinson Cancer Research Center.  He completed a degree in Pharmacy from Oregon State University in 1983, a master’s degree in Administrative and Economic Sciences from the University of Texas in 1986 and earned a PhD in Health Economics and Policy from the University of California, Berkeley in 1991.

Dr Sullivan is Past President of the International Society for Pharmacoeconomics and Outcomes Research.  He has authored more than 200 journal articles, book chapters, and organizational and governmental publications, including many on methods and applications of evidence-based technology assessment to coverage and reimbursement decisions.  Dr Sullivan’s research interests include technology assessment, medical decision making, and economic evaluation of medical technology. Dr. Sullivan also is a member of the Medicare Coverage Advisory Committee (MCAC).  Dr Sullivan is an editor for Value in Health and a member of the editorial board of PharmacoEconomics.

His clinical interests are in respiratory disease where he is a member of the scientific committee of the Global Initiative for Asthma (GINA) and a past member of the Global Initiative for Chronic Obstructive Lung Disease (GOLD). He has also served as a member of the National Asthma Education and Prevention Program Task Force on the Cost-Effectiveness, Quality of Care, and Financing of Asthma Care of the National Heart, Lung, and Blood Institute.

David Veenstra, PharmD, PhD, Associate Professor of Pharmacy
veenstra@u.washington.edu

Dr. Veenstra graduated from the University of California San Francisco, where he completed concurrent doctoral programs in clinical pharmacy and medicinal chemistry in 1996. He studied the effect of amino acid mutations on protein stability using computer modeling techniques. Dr. Veenstra conducted his postdoctoral training in pharmacoeconomics with the University of Washington from 1997-1999, and spent one year working with Roche Global Pharmacoeconomics in Palo Alto, CA.

Dr. Veenstra is an Associate Professor in the Pharmaceutical Outcomes Research and Policy Program (PORPP) in the Department of Pharmacy. His methodological expertise is in cost-effectiveness modeling, including decision analysis, Markov modeling, and Monte Carlo simulation. Dr. Veenstra’s primary research interests are the clinical, economic, and policy implications of pharmacogenomic-based drug therapies. His projects include studying the association between drug metabolizing enzymes and adverse drug reactions, estimating the cost-effectiveness of pharmacogenomic interventions, and evaluating the impact of pharmacogenomics on the health care system and pharmaceutical industry.

Dr. Veenstra also has significant experience in modeling chronic diseases such as diabetes, hyperlipidemia, hypertension, and hepatitis B and C. Recently, as part of an Academy of Managed Care Pharmacy (AMCP) educational program, Dr. Veenstra has been working with Pharmacy and Therapeutics committees to assist them in evaluating cost-effectiveness models submitted to health care plans by manufacturers.

Dr. Veenstra is a member of the Society for Medical Decision Making, the International Society for Pharmacoeconomics and Outcomes Research, and the American Association for the Advancement of Science. Dr. Veenstra is a recipient of the PhRMA Foundation Career Development Award in Pharmacoeconomics.